The Medical Technologies Innovation Facility (MTIF) is delighted to announce three key appointments to its leadership team.
Jacqui Hayes joins us with over thirty years of experience in medical technology and pharmaceutical business development. Using her expertise in building collaborative partnerships Jacqui will develop our commercial offering enabling organisations to accelerate the exploitation of their innovative technologies to improve outcomes for patients. Jacqui was most recently Global Business Development and Licensing Manager within 3M’s Drug Delivery Division and joined us on 1st April 2020.
Max Bardwell is moving from his role as Strategic Partnership Manager at Nottingham Trent University to MTIF as Senior Business Development Manager. Working alongside Jacqui, Max will develop our commercial and partnership offer building on his extensive experience of commercialising academic capability for the benefit of industry. Max is transitioning into the new role and will be with us full time from the middle of May.
Robert Reisel is our latest recruit and will take up his position as Technical Director on 1st June. Joining us from Paul Hartmann AG in Germany, Robert brings extensive medical technology expertise. Robert has led large, complex, multi-disciplinary projects taking innovative Class I, Class II and Class III products from concept through to launch. Robert will bring together our industry leading technical capabilities and ensure projects are delivered in accordance with MDR2017/745 and IVDR2017/746 through our ISO13485 Quality Management System.
Mike Hannay, Managing Director, MTIF, said “I am thrilled that three such highly talented individuals are joining MTIF. All three will play a pivotal role in driving the MTIF’s future growth and come to us with an impressive track record of delivering sustained growth and market success in each of their previous roles. I look forward to working with Jacqui, Max and Robert to accelerate the development of innovative medical technologies from bench to bedside for the benefit of patients and clinicians.”